US8816242098

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 ReinforcingBest-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohns DiseaseTeva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 ReinforcingBest-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohns Disease

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 ReinforcingBest-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohns Disease

Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET February 22, 2025 02:20 ET  | Source: Teva…

3 weeks ago
Teva to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceTeva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 23, 2024 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) --…

3 months ago
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in JapanTeva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

December 05, 2024 18:00 ET | Source: Teva Pharmaceutical Industries Ltd Teva entered into an agreement with JKI Co., Ltd.…

3 months ago
Teva to Present at the Jefferies London Healthcare ConferenceTeva to Present at the Jefferies London Healthcare Conference

Teva to Present at the Jefferies London Healthcare Conference

November 08, 2024 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) --…

4 months ago